Results 211 to 220 of about 2,066,293 (312)

Patient pathways, presentation time, time to diagnosis, and early survival outcomes in pediatric acute lymphoblastic leukemia at Muhimbili National Hospital, Dar es Salaam, Tanzania. [PDF]

Front Pediatr
Philbert R, Mwamtemi H, Okade T, Mutyaba H, Ndyetabula L, Shimba E, Nakiddu NJ, Elisha E, Safari WC, Chiwanga F, Chirande L.   +10 more
europepmc   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Beyond the label: patient-reported outcomes and post-approval communication in oncology. [PDF]

BMJ Oncol
Lehmann J.
europepmc   +1 more source

Association of Burnout With Missed Nursing Care Among Neuro-Oncology Nurses: The Mediating Role of Professional Identity and the Moderating Role of Psychological Capital. [PDF]

Nurs Open
Ying L, Yuyu D, Huidan L, Ping Z, Yangmei S, Xiaowei Z, Zhihuan Z.   +6 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey. [PDF]

J Neurooncol
Hönikl LS, Lange S, Meyer B, Combs SE, Lörsch AM, Illert AL, Wagner A, Schmidt-Graf F.   +7 more
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices. [PDF]

JCO Precis Oncol
Evangelist M, Wang B, Butrynski JE, Paschold J, Ward PJ, Waterhouse DM, Jotte RM, Ali K, Richards DA, Konduri K, Melnyk A, Owera RS, Hakimian D, Ghaddar H, Lander EM, Robert NJ, Yori JL, Upadhyay V, Spigel DR, Johnson ML.   +19 more
europepmc   +1 more source